ONO PHARMA partners with Bristol Myers SquibbBristol-Myers Squibb ( BMY ), Bayer and Ono Pharmaceutical (OPHLY) have entered into a clinical collaboration agreement to evaluate the combination of Bayer's kinase inhibitor Stivarga and Bristol-Myers Squibb's / Ono's anti-PD-1 immune checkpoint inhibitor, Opdivo in patients with micro-satellite s
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.0 EUR
783.64 M EUR
3.08 B EUR
328.10 M
About ONO PHARMACEUTICAL CO
Sector
Industry
CEO
Gyo Sagara
Website
Headquarters
Osaka
Founded
1947
ISIN
JP3197600004
FIGI
BBG000C4Q8N6
Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of internal medicine, patch and injectable medicine. The company was founded by Ichibei Fushimiya in 1717 and is headquartered in Osaka, Japan.
ONO PHARMA partners with Bristol Myers SquibbTODAY'S ANNOUNCEMENT
Bristol-Myers Squibb (BMY), Bayer and Ono Pharmaceutical (OPHLY) have entered into a clinical collaboration agreement to evaluate the combination of Bayer's kinase inhibitor Stivarga and Bristol-Myers Squibb's / Ono's anti-PD-1 immune checkpoint inhibitor, Opdivo in patients wi
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange ONO PHARMACEUT. stocks are traded under the ticker ON4.
We've gathered analysts' opinions on ONO PHARMACEUT. future price: according to them, ON4 price has a max estimate of 15.39 EUR and a min estimate of 8.62 EUR. Watch ON4 chart and read a more detailed ONO PHARMACEUT. stock forecast: see what analysts think of ONO PHARMACEUT. and suggest that you do with its stocks.
Yes, you can track ONO PHARMACEUT. financials in yearly and quarterly reports right on TradingView.
ONO PHARMACEUT. is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
ON4 earnings for the last quarter are 0.20 EUR per share, whereas the estimation was 0.26 EUR resulting in a −23.96% surprise. The estimated earnings for the next quarter are 0.14 EUR per share. See more details about ONO PHARMACEUT. earnings.
ONO PHARMACEUT. revenue for the last quarter amounts to 824.62 M EUR, despite the estimated figure of 805.48 M EUR. In the next quarter, revenue is expected to reach 749.13 M EUR.
ON4 net income for the last quarter is 91.78 M EUR, while the quarter before that showed 105.35 M EUR of net income which accounts for −12.88% change. Track more ONO PHARMACEUT. financial stats to get the full picture.
ONO PHARMACEUT. dividend yield was 3.26% in 2023, and payout ratio reached 30.01%. The year before the numbers were 2.53% and 30.32% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Apr 18, 2025, the company has 3.85 K employees. See our rating of the largest employees — is ONO PHARMACEUT. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ONO PHARMACEUT. EBITDA is 690.32 M EUR, and current EBITDA margin is 36.15%. See more stats in ONO PHARMACEUT. financial statements.
Like other stocks, ON4 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ONO PHARMACEUT. stock right from TradingView charts — choose your broker and connect to your account.